SPRY
ARS Pharmaceuticals, Inc.
$4.03
-6.71%
2026-10-23
About ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
Key Fundamentals
Forward P/E
-4.55
EPS (TTM)
$-2.18
ROE
-210.3%
Revenue Growth (YoY)
114.2%
Profit Margin
-184.2%
Debt/Equity
1371.51
Price/Book
32.38
Beta
1.00
Market Cap
$405.7M
Avg Volume (10D)
1.8M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$6.58
60D Low
$3.81
Avg Volume
1.6M
Latest Close
$4.03
Get breakout alerts for SPRY
Sign up for Breakout Scanner to receive daily notifications when SPRY triggers breakout signals. Build custom AI screeners and backtest strategies.
Create your account7-day free trial, no card needed. Then $20/month.
ARS Pharmaceuticals, Inc. (SPRY) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors SPRY daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. SPRY operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.